Literature DB >> 16638927

Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options.

Didier Decaudin1, Patricia de Cremoux, Anne Vincent-Salomon, Remi Dendale, Livia Lumbroso-Le Rouic.   

Abstract

The recent literature shows that interest in ocular adnexal lymphomas and their biologic and clinical characteristics--along with their possible association with Chlamydia psittaci infection and therapeutic management with rituximab or anti-Chlamydia psittaci antibiotic therapy--is considerable. These new data have modified the previously reported features of this disease and have made an updated review of the literature necessary. The aims of this review are to present the current knowledge on the biology of these lymphomas, their clinical features and prognostic factors, and the panel of all available treatment options.

Entities:  

Mesh:

Year:  2006        PMID: 16638927     DOI: 10.1182/blood-2006-02-005017

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  Orbital and ocular adnexal Mucosa-Associated Lymphoid Tissue (MALT) lymphomas: a single-center 10-year experience.

Authors:  M Smiljanic; R Milosevic; D Antic; B Andjelic; V Djurasinovic; M Todorovic; J Bila; A Bogdanovic; B Mihaljevic
Journal:  Med Oncol       Date:  2013-09-13       Impact factor: 3.064

2.  Histopathological Features and Ann Arbor Stage in Periocular Lymphoma.

Authors:  Marco Zschoche; Annette Zimpfer; Björn O Scheef; Anselm M Jünemann; Rudolf F Guthoff; Christian Junghanss; Guido Hildebrandt; Steffen Emmert; Andreas Erbersdobler; Günther Kundt; Vinodh Kakkassery
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

3.  Mutation analysis of NF-κB signal pathway-related genes in ocular MALT lymphoma.

Authors:  Fang Liu; Kennosuke Karube; Harumi Kato; Kotaro Arita; Noriaki Yoshida; Kiyoko Yamamoto; Shinobu Tsuzuki; Wonseog Kim; Young-Hyeh Ko; Masao Seto
Journal:  Int J Clin Exp Pathol       Date:  2012-05-23

4.  Clinical features and treatment outcomes of primary ocular adnexal mucosa-associated lymphoid tissue lymphoma: a single center retrospective analysis of 64 patients in China.

Authors:  Hui Yu; Yu-Xin Du; Zhen-Chang Sun; Xiao-Rui Fu; Nan Tan; Wei-Feng Gong; Ming-Zhi Zhang
Journal:  Int J Ophthalmol       Date:  2019-11-18       Impact factor: 1.779

5.  MicroRNA-200 is commonly repressed in conjunctival MALT lymphoma, and targets cyclin E2.

Authors:  Jiping Cai; Xiaoyu Liu; Jinwei Cheng; You Li; Xiao Huang; Yuzhen Li; Xiaoye Ma; Hongyu Yu; Huimin Liu; Ruili Wei
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-20       Impact factor: 3.117

Review 6.  Ocular adnexal marginal zone lymphoma of mucosa-associated lymphoid tissue.

Authors:  Dimitrios Kalogeropoulos; Alexandra Papoudou-Bai; Panagiotis Kanavaros; Chris Kalogeropoulos
Journal:  Clin Exp Med       Date:  2017-09-22       Impact factor: 3.984

7.  Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): single institution experience in a large cohort of patients.

Authors:  Soley Bayraktar; Ulas D Bayraktar; Alexandra Stefanovic; Izidore S Lossos
Journal:  Br J Haematol       Date:  2010-11-18       Impact factor: 6.998

8.  Primary bilateral small lymphocytic lymphoma of ocular adnexal origin: Imprint cytology suggests the intraoperative diagnosis.

Authors:  Arghya Bandyopadhyay; Kaushik Majumdar; Mimi Gangopadhyay; Kalyan Khan; Subrata Chakraborty; Asim Kr Ghosh
Journal:  Saudi J Ophthalmol       Date:  2012-03-29

9.  [Salmon-pink colored conjunctival tumor with amyloid deposits].

Authors:  P L Müller; K U Loeffler; F G Holz; H-P Fischer; M C Herwig
Journal:  Ophthalmologe       Date:  2016-07       Impact factor: 1.059

10.  Use of similar immunoglobulin VH gene segments by MALT lymphomas of the ocular adnexa.

Authors:  David W Bahler; Philippe Szankasi; Sucheta Kulkarni; Raymond R Tubbs; James R Cook; Steven H Swerdlow
Journal:  Mod Pathol       Date:  2009-06       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.